You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Docetaxel for the treatment of hormone-refractory metastatic prostate cancer

  • Technology appraisal guidance
  • Reference number: TA101
  • Published:  28 June 2006
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive Appendix A: decision paper presented to the Institute's Guidance Executive
15 May 2012
(110.66 Kb 32 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 14 May 2012

Back to top